Patients with stages I and II Hodgkin lymphoma (HL) treated by doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy followed by radiotherapy have high cure rates, with progression-free survival (PFS) rates at 5 years of approximately 95% for favorable and 87% for unfavorable risk groups.¹ An interim 18-fluorine–labeled fluorodeoxyglucose positron emission tomography (PET) scan performed early during chemotherapy may identify patients who need reduced or more intensive treatments. Good responders may avoid the toxicity and adverse effects of radiotherapy, whereas poor responders would benefit from treatment intensification.² The potential of interim PET was tested in the H10 trial in patients ages 15 to 70 years with supradiaphragmatic stages I and II HL; these results were recently reported in Journal of Clinical Oncology by André et al.³ The study included 754 patients with favorable HL and 1,196 patients with unfavorable disease, according to the European Organisation for Research and Treatment of Cancer criteria. Our comment focuses on the group of patients with favorable HL.

中文翻译：

---

中期氟18标记的氟脱氧葡萄糖正电子发射断层扫描在早期早期良性霍奇金淋巴瘤中的作用

接受阿霉素，博来霉素，长春碱和达卡巴嗪（ABVD）化疗并放疗的I期和II期霍奇金淋巴瘤（HL）患者治愈率很高，5年无进展生存率（PFS）约为95％有利，而对于不利风险组，这一比例为87％。¹在化疗期间早期进行的中期18氟标记的氟脱氧葡萄糖正电子发射断层扫描（PET）扫描可能会确定需要减少治疗或加强治疗的患者。良好的反应者可以避免放疗的毒性和不良反应，而较差的反应者将从强化治疗中受益。^2个H10试验在15到70岁患有sup上I裂I期和II期HL的患者中测试了临时PET的潜力；这些结果最近发表在André等人的《临床肿瘤学杂志》上。³根据欧洲癌症研究与治疗组织的标准，该研究包括754例HL喜好患者和1,196例疾病不利的患者。我们的评论集中在HL良好的患者群体上。